Hepatitis C Drugs Market to Surpass US$ 10,110.4 Million by 2027 | Abbvie, Gilead sciences, BRISTOL-MYERS Squibb Company

Hepatitis C virus is a blood-borne virus that infects liver cells, resulting in illness that ranges from mild and transient effects such as easy bleeding, fatigue, yellow discoloration of skin and eyes, and others to chronic and serious life-threatening conditions such as liver cirrhosis, liver cancer or liver failure. Hepatitis C virus is transmitted through needlestick injuries, organ transplant from a carrier, and sexually or from infected mother to fetus.

Globally, hepatitis C virus exists in six distinct forms based on its genotypes, amongst which Type 1 is the most common form representing around 60-70% of global infections. Hepatitis C is diagnosed by blood tests for estimating viral load and genotyping, and liver damage tests such as magnetic resonance elastography (MRE), transient elastography, and liver biopsy. Antiviral drugs, which inhibits protease or polymerase enzyme of virus is one of the treatments available for infection caused due to hepatitis C. Currently, no vaccines are available for the prevention of hepatitis C virus and this provides scope for the market players to expand their company portfolio.

Get a Sample Copy + All Related Graphs & Charts @: https://www.coherentmarketinsights.com/insight/request-sample/1489

Increasing prevalence of hepatitis C is expected to drive growth of hepatitis C drugs market over the forecast period. For instance, in 2018, according to the Centers for Disease Control and Prevention (CDC), around 3.9 million of U.S. population suffered from hepatitis C. Hepatitis C virus (HCV) infection is a commonly found blood borne infection in the U.S.

Moreover, in Canada, 246,000 number of Canada population suffered with HCV disease in 2017, wherein around 44% were unaware about HCV infection.

However, high cost of hepatitis C treatment is expected to hamper growth of the hepatitis C drugs market during the forecast period. For instance, in the U.S., a 12-week course of Sovaldi costs around US$ 84,000, where one pill costs around US$ 1,000. Similarly, Olysio drug costs around US$ 23,600 per month of hepatitis C treatment and treatment period for this drug was around 24-48 weeks.

Detailed Segmentation:

by Drug Type:
Interferon Based Therapies
NS5A Inhibitors
NS5B Inhibitors
Protease Inhibitors
by Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Company Profiles
Abbvie Inc *
Gilead sciences, Inc.
BRISTOL-MYERS Squibb Company.
F Hoffmann-la Roche Ltd
Merck & co., Inc.
Johnson & Johnson
Natco Pharma Limited
Kadmon holdings, Inc.

Buy This Complete A Business Report: https://www.coherentmarketinsights.com/insight/buy-now/1489

Hepatitis C is a major liver disease, and it has become a global burden. Moreover, key players are focused on developing new drugs for the treatment of hepatitis C. Increasing launches of new drugs is expected to drive the hepatitis C drugs market growth. For instance, in 2019, The AbbVie Inc. company received the U.S. Food and Drug Administration approval for Mavyret (glecaprevir and pibrentasvir) tablets to treat all six genotypes of hepatitis C virus (HCV) in children of age group of 12 to 17.

Moreover, in 2018, Nacto Pharma ltd launched a drug with brand name as Hepcinat Plus for the treatment of hepatitis C disease. This drug is generic form and fixed combination of Sofosbuvir-Declatasvir tablet. The company launched this drug at a retail price of US$ 246.1 for 28 tablets.

Furthermore, in 2018, Gilead Sciences Company launched generic versions of Harvoni and Epclusa, which was valued at US$ 24,000 for full course of therapy. The launch of these drugs helped to resolve the issue related to high cost of branded drugs, which is around US$ 100,000 for full course of therapy.

Coherent Market Insights 1001 4th Ave,
#3200 Seattle, WA 98154,U.S.
Phone: US +1-206-701-6702/UK +44-020 8133 4027
Email: sales@coherentmarketinsights.com

About Us:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.